Skip to main content

GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep Apnea

Medically reviewed by Carmen Pope, BPharm. Last updated on June 23, 2024.

By Carole Tanzer Miller HealthDay Reporter

FRIDAY, June 21, 2024 -- A medication used to manage type 2 diabetes has been found effective in treating sleep apnea.

The worldwide clinical trial demonstrates that tirzepatide significantly lowers breathing interruptions during sleep, a key indicator of the severity of a patient's obstructive sleep apnea (OSA).

Tirzepatide is one of the class of blockbuster GLP-1 medicines, sold as Mounjaro to fight diabetes and as Zepbound to help with weight loss.

"This study marks a significant milestone in the treatment of OSA, offering a promising new therapeutic option that addresses both respiratory and metabolic complications," said study leader Dr. Atul Malhotra, director of sleep medicine at UC San Diego Health.

OSA is characterized by repeated episodes of irregular breathing during sleep due to total or partial blockage of the upper airway. It can result in reduced oxygen levels in the blood and has been linked to an increased risk for high blood pressure, heart disease and other heart-related complications.

More than 900 million people worldwide are believed to have OSA, and the 469 participants in this study were recruited from the United States and eight other countries. All were clinically obese and had moderate-to-severe sleep apnea.

Some used continuous positive airway pressure (CPAP) treatment, in which a machine maintains an open airway during sleep. All were given 10 or 15 milligrams (mg) of tirzepatide or a placebo.

Over the course of one year, patients who used tirzepatide had a significant drop in breathing interruptions during sleep. Their improvement was much greater than that seen in the placebo group. Researchers said some patients might no longer need CPAP therapy.

The findings, published June 21 in the New England Journal of Medicine, add to evidence that a drug targeting both apnea and obesity is better than treating either condition on its own. Researchers said the drug therapy improved other aspects related to OSA, such as improving weight. Some patients, however, had mild stomach issues.

For patients who hate wearing a CPAP mask over their nose and mouth when they go to bed, the findings could be welcome news.

"This breakthrough opens the door to a new era of OSA management for people diagnosed with obesity, potentially transforming how we approach and treat this pervasive condition on a global scale," Malhotra said in a UC San Diego Health news release.

Sources

  • UC San Diego Health, news release, June 21, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Most Women Aren't Clear When Menopause Might Start

FRIDAY, April 11, 2025 -- Early symptoms of menopause will first appear when many women least expect them, a new Ohio State University poll reports. Hot flashes, mood swings...

Why Are Night Owls Prone To Depression?

FRIDAY, March 21, 2025 -- Night owls -- people who stay up late -- have been shown to have an increased risk of depression. And now a new study says why that might be. Dusk...

Tonsil Removal Helps Kids With Snoring/Sleep Apnea

THURSDAY, March 20, 2025 -- Removing the tonsils and adenoids can improve the sleep of kids with mild breathing problems that disturb their slumber, a new clinical trial...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.